
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1372498/publications.pdf Version: 2024-02-01



ΙΔΝΙ ΔΝΙ ΗΔΔΥΙΚ

#	Article	IF	CITATIONS
1	Reproducibility in the absence of selective reporting: AnÂillustration from largeâ€scale brain asymmetry research. Human Brain Mapping, 2022, 43, 244-254.	3.6	16
2	Consortium neuroscience of attention deficit/hyperactivity disorder and autism spectrum disorder: The <scp>ENIGMA</scp> adventure. Human Brain Mapping, 2022, 43, 37-55.	3.6	61
3	Effects of copy number variations on brain structure and risk for psychiatric illness: Largeâ€scale studies from the <scp>ENIGMA</scp> working groups on <scp>CNVs</scp> . Human Brain Mapping, 2022, 43, 300-328.	3.6	30
4	Familial co-aggregation of attention-deficit/hyperactivity disorder and autoimmune diseases: a cohort study based on Swedish population-wide registers. International Journal of Epidemiology, 2022, 51, 898-909.	1.9	12
5	Non-mental diseases associated with ADHD across the lifespan: Fidgety Philipp and Pippi Longstocking at risk of multimorbidity?. Neuroscience and Biobehavioral Reviews, 2022, 132, 1157-1180.	6.1	22
6	ADHD symptoms in neurometabolic diseases: Underlying mechanisms and clinical implications. Neuroscience and Biobehavioral Reviews, 2022, 132, 838-856.	6.1	18
7	Association of sweetened carbonated beverage consumption during pregnancy and ADHD symptoms in the offspring: a study from the Norwegian Mother, Father and Child Cohort Study (MoBa). European Journal of Nutrition, 2022, 61, 2153-2166.	3.9	3
8	Innovative approaches in investigating interâ€beat intervals: Graph theoretical method suggests altered autonomic functioning in adolescents with ADHD. Psychophysiology, 2022, , e14005.	2.4	1
9	Vagally mediated heart rate variability, stress, and perceived social support: a focus on sex differences. Stress, 2022, 25, 113-121.	1.8	7
10	Insulinopathies of the brain? Genetic overlap between somatic insulin-related and neuropsychiatric disorders. Translational Psychiatry, 2022, 12, 59.	4.8	39
11	Virtual Ontogeny of Cortical Growth Preceding Mental Illness. Biological Psychiatry, 2022, 92, 299-313.	1.3	11
12	Gene-Environment Interactions in Attention-Deficit/Hyperactivity Disorder Symptom Dimensions: The Role of Unhealthy Food Habits. Genes, 2022, 13, 47.	2.4	4
13	Druggable genome in attention deficit/hyperactivity disorder and its co-morbid conditions. New avenues for treatment. Molecular Psychiatry, 2021, 26, 4004-4015.	7.9	27
14	Diet quality, stress and common mental health problems: A cohort study of 121,008 adults. Clinical Nutrition, 2021, 40, 901-906.	5.0	29
15	Individual Variability in Reaction Time and Prediction of Clinical Response to Methylphenidate in Adult ADHD: A Prospective Open Label Study Using Conners' Continuous Performance Test II. Journal of Attention Disorders, 2021, 25, 657-671.	2.6	9
16	Structure and substrate specificity determinants of the taurine biosynthetic enzyme cysteine sulphinic acid decarboxylase. Journal of Structural Biology, 2021, 213, 107674.	2.8	3
17	Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. JAMA Psychiatry, 2021, 78, 47.	11.0	136
18	Test–Retest Reliability of the 25-item version of Wender Utah Rating Scale. Impact of Current ADHD Severity on Retrospectively Assessed Childhood Symptoms. Journal of Attention Disorders, 2021, 25, 1001-1009.	2.6	8

#	Article	IF	CITATIONS
19	Characterizing neuroanatomic heterogeneity in people with and without ADHD based on subcortical brain volumes. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2021, 62, 1140-1149.	5.2	14
20	1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans. Translational Psychiatry, 2021, 11, 182.	4.8	24
21	Analysis of structural brain asymmetries in attentionâ€deficit/hyperactivity disorder in 39 datasets. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2021, 62, 1202-1219.	5.2	40
22	Cysteine Modification by Ebselen Reduces the Stability and Cellular Levels of 14-3-3 Proteins. Molecular Pharmacology, 2021, 100, 155-169.	2.3	9
23	Comorbidity of ADHD and adult bipolar disorder: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2021, 124, 100-123.	6.1	71
24	Diet, Physical Activity, and Disinhibition in Middle-Aged and Older Adults: A UK Biobank Study. Nutrients, 2021, 13, 1607.	4.1	3
25	Genetic association study of childhood aggression across raters, instruments, and age. Translational Psychiatry, 2021, 11, 413.	4.8	31
26	Continuity of Genetic Risk for Aggressive Behavior Across the Life-Course. Behavior Genetics, 2021, 51, 592-606.	2.1	13
27	Synthetic corticosteroids as tryptophan hydroxylase stabilizers. Future Medicinal Chemistry, 2021, 13, 1465-1474.	2.3	2
28	Male to female ratios in autism spectrum disorders by age, intellectual disability and attentionâ€deficit/hyperactivity disorder. Acta Psychiatrica Scandinavica, 2021, 144, 635-646.	4.5	41
29	Investigating Shared Genetic Basis Across Tourette Syndrome and Comorbid Neurodevelopmental Disorders Along the Impulsivity-Compulsivity Spectrum. Biological Psychiatry, 2021, 90, 317-327.	1.3	49
30	An Exploratory Investigation of Goal Management Training in Adults With ADHD: Improvements in Inhibition and Everyday Functioning. Frontiers in Psychology, 2021, 12, 659480.	2.1	15
31	The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neuroscience and Biobehavioral Reviews, 2021, 128, 789-818.	6.1	483
32	Sex differences in parent–offspring recurrence of attentionâ€deficit/hyperactivity disorder. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2021, 62, 1010-1018.	5.2	10
33	Personalized Medicine to Improve Treatment of Dopa-Responsive Dystonia—A Focus on Tyrosine Hydroxylase Deficiency. Journal of Personalized Medicine, 2021, 11, 1186.	2.5	6
34	Dose response of the 16p11.2 distal copy number variant on intracranial volume and basal ganglia. Molecular Psychiatry, 2020, 25, 584-602.	7.9	49
35	Identification of ADHD risk genes in extended pedigrees by combining linkage analysis and whole-exome sequencing. Molecular Psychiatry, 2020, 25, 2047-2057.	7.9	17
36	Tyrosinemia Type 1 and symptoms of ADHD: Biochemical mechanisms and implications for treatment and prognosis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2020, 183, 95-105.	1.7	15

#	Article	IF	CITATIONS
37	Cyclothymic temperament: Associations with ADHD, other psychopathology, and medical morbidity in the general population. Journal of Affective Disorders, 2020, 260, 440-447.	4.1	14
38	Association of Copy Number Variation of the 15q11.2 BP1-BP2 Region With Cortical and Subcortical Morphology and Cognition. JAMA Psychiatry, 2020, 77, 420.	11.0	54
39	Serine 19 phosphorylation and 14â€3â€3 binding regulate phosphorylation and dephosphorylation of tyrosine hydroxylase on serine 31 and serine 40. Journal of Neurochemistry, 2020, 152, 29-47.	3.9	9
40	International Consortium on the Genetics of Electroconvulsive Therapy and Severe Depressive Disorders (Gen-ECT-ic). European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 921-932.	3.2	22
41	Identification of Genetic Loci Shared Between Attention-Deficit/Hyperactivity Disorder, Intelligence, and Educational Attainment. Biological Psychiatry, 2020, 87, 1052-1062.	1.3	13
42	GADL1 is a multifunctional decarboxylase with tissue-specific roles in \hat{I}^2 -alanine and carnosine production. Science Advances, 2020, 6, eabb3713.	10.3	27
43	Inhibition of Tryptophan Hydroxylases and Monoamine Oxidase-A by the Proton Pump Inhibitor, Omeprazole—In Vitro and In Vivo Investigations. Frontiers in Pharmacology, 2020, 11, 593416.	3.5	10
44	Current and Retrospective Childhood Ratings of Emotional Fluctuations in Adults With ADHD. Frontiers in Psychology, 2020, 11, 571101.	2.1	3
45	Discovery and biological characterization of a novel scaffold for potent inhibitors of peripheral serotonin synthesis. Future Medicinal Chemistry, 2020, 12, 1461-1474.	2.3	10
46	Anterior cingulate gammaâ€aminobutyric acid concentrations and electroconvulsive therapy. Brain and Behavior, 2020, 10, e01833.	2.2	11
47	Subcortical Brain Volume, Regional Cortical Thickness, and Cortical Surface Area Across Disorders: Findings From the ENIGMA ADHD, ASD, and OCD Working Groups. American Journal of Psychiatry, 2020, 177, 834-843.	7.2	120
48	Involvement of the 14-3-3 Gene Family in Autism Spectrum Disorder and Schizophrenia: Genetics, Transcriptomics and Functional Analyses. Journal of Clinical Medicine, 2020, 9, 1851.	2.4	14
49	Insomnia, Alcohol Consumption and ADHD Symptoms in Adults. Frontiers in Psychology, 2020, 11, 1150.	2.1	6
50	Attention-deficit/hyperactivity disorder and smoking habits in pregnant women. PLoS ONE, 2020, 15, e0234561.	2.5	8
51	Shared genetic background between children and adults with attention deficit/hyperactivity disorder. Neuropsychopharmacology, 2020, 45, 1617-1626.	5.4	72
52	Validity and accuracy of the Adult Attentionâ€Deficit/Hyperactivity Disorder (ADHD) Selfâ€Report Scale (ASRS) and the Wender Utah Rating Scale (WURS) symptom checklists in discriminating between adults with and without ADHD. Brain and Behavior, 2020, 10, e01605.	2.2	39
53	Alcohol and drug use disorders in adult attention-deficit/hyperactivity disorder: Prevalence and associations with attention-deficit/hyperactivity disorder symptom severity and emotional dysregulation. World Journal of Psychiatry, 2020, 10, 202-211.	2.7	19
54	Attention-deficit hyperactivity disorder shares copy number variant risk with schizophrenia and autism spectrum disorder. Translational Psychiatry, 2019, 9, 258.	4.8	75

#	Article	IF	CITATIONS
55	Patterns of Psychiatric Comorbidity and Genetic Correlations Provide New Insights Into Differences Between Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder. Biological Psychiatry, 2019, 86, 587-598.	1.3	41
56	The effect of electroconvulsive therapy (ECT) on serum tryptophan metabolites. Brain Stimulation, 2019, 12, 1135-1142.	1.6	20
57	Brain Imaging of the Cortex in ADHD: A Coordinated Analysis of Large-Scale Clinical and Population-Based Samples. American Journal of Psychiatry, 2019, 176, 531-542.	7.2	261
58	Effect of disease-associated SLC9A9 mutations on protein–protein interaction networks: implications for molecular mechanisms for ADHD and autism. ADHD Attention Deficit and Hyperactivity Disorders, 2019, 11, 91-105.	1.7	12
59	Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. Cell, 2019, 179, 1469-1482.e11.	28.9	935
60	Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nature Genetics, 2019, 51, 63-75.	21.4	1,594
61	The quaternary structure of human tyrosine hydroxylase: effects of dystoniaâ€associated missense variants on oligomeric state and enzyme activity. Journal of Neurochemistry, 2019, 148, 291-306.	3.9	20
62	Occupational Status Is Compromised in Adults With ADHD and Psychometrically Defined Executive Function Deficits. Journal of Attention Disorders, 2019, 23, 76-86.	2.6	27
63	Verbal Memory Function in Intellectually Well-Functioning Adults With ADHD: Relations to Working Memory and Response Inhibition. Journal of Attention Disorders, 2019, 23, 1188-1198.	2.6	17
64	Health Care Services for Adults With ADHD: Patient Satisfaction and the Role of Psycho-Education. Journal of Attention Disorders, 2019, 23, 99-108.	2.6	24
65	Females With ADHD Report More Severe Symptoms Than Males on the Adult ADHD Self-Report Scale. Journal of Attention Disorders, 2019, 23, 959-967.	2.6	23
66	Structure of the mouse acidic amino acid decarboxylase GADL1. Acta Crystallographica Section F, Structural Biology Communications, 2018, 74, 65-73.	0.8	8
67	Novel Loci Associated With Attention-Deficit/Hyperactivity Disorder Are Revealed by Leveraging Polygenic Overlap With Educational Attainment. Journal of the American Academy of Child and Adolescent Psychiatry, 2018, 57, 86-95.	0.5	30
68	Adult ADHD and Comorbid Somatic Disease: A Systematic Literature Review. Journal of Attention Disorders, 2018, 22, 203-228.	2.6	148
69	Moderating effect of mode of delivery on the genetics of intelligence: Explorative genomeâ€wide analyses in ALSPAC. Brain and Behavior, 2018, 8, e01144.	2.2	6
70	Common psychiatric and metabolic comorbidity of adult attention-deficit/hyperactivity disorder: A population-based cross-sectional study. PLoS ONE, 2018, 13, e0204516.	2.5	125
71	Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. European Neuropsychopharmacology, 2018, 28, 1059-1088.	0.7	398
72	Mapping cortical brain asymmetry in 17,141 healthy individuals worldwide via the ENIGMA Consortium. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5154-E5163.	7.1	299

#	Article	IF	CITATIONS
73	Event-Related-Potential (ERP) Correlates of Performance Monitoring in Adults With Attention-Deficit Hyperactivity Disorder (ADHD). Frontiers in Psychology, 2018, 9, 485.	2.1	35
74	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	12.6	1,085
75	Associations between attention-deficit/hyperactivity disorder and autoimmune diseases are modified by sex: a population-based cross-sectional study. European Child and Adolescent Psychiatry, 2018, 27, 663-675.	4.7	48
76	Attention-Deficit/Hyperactivity Disorder in Offspring of Mothers With Inflammatory and Immune System Diseases. Biological Psychiatry, 2017, 81, 452-459.	1.3	141
77	<i><scp>SLC</scp>2A3</i> singleâ€nucleotide polymorphism and duplication influence cognitive processing and populationâ€specific risk for attentionâ€deficit/hyperactivity disorder. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2017, 58, 798-809.	5.2	25
78	Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults: a cross-sectional mega-analysis. Lancet Psychiatry,the, 2017, 4, 310-319.	7.4	565
79	Tyrosine and tryptophan hydroxylases as therapeutic targets in human disease. Expert Opinion on Therapeutic Targets, 2017, 21, 167-180.	3.4	52
80	640. Lipidomics in Patients Receiving ECT. Biological Psychiatry, 2017, 81, S259.	1.3	0
81	Implication of the APP Gene in Intellectual Abilities. Journal of Alzheimer's Disease, 2017, 59, 723-735.	2.6	13
82	Adults with Attention Deficit Hyperactivity Disorder Report High Symptom Levels of Troubled Sleep, Restless Legs, and Cataplexy. Frontiers in Psychology, 2017, 8, 1621.	2.1	24
83	Vitamin levels in adults with ADHD. BJPsych Open, 2016, 2, 377-384.	0.7	25
84	A candidate gene investigation of methylphenidate response in adult attention-deficit/hyperactivity disorder patients: results from a naturalistic study. Journal of Neural Transmission, 2016, 123, 859-865.	2.8	12
85	Meta-analysis of the DRD5 VNTR in persistent ADHD. European Neuropsychopharmacology, 2016, 26, 1527-1532.	0.7	4
86	Genomeâ€wide analyses of aggressiveness in attentionâ€deficit hyperactivity disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2016, 171, 733-747.	1.7	40
87	Regulation of tyrosine hydroxylase is preserved across different homo- and heterodimeric 14-3-3 proteins. Amino Acids, 2016, 48, 1221-1229.	2.7	16
88	Personality Traits and Comorbidity in Adults With ADHD. Journal of Attention Disorders, 2016, 20, 845-854.	2.6	24
89	On the role of <i>NOS1</i> ex1fâ€VNTR in ADHD—allelic, subgroup, and metaâ€analysis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2015, 168, 445-458.	1.7	20
90	Epistatic and gene wide effects in YWHA and aromatic amino hydroxylase genes across ADHD and other common neuropsychiatric disorders: Association with YWHAE. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2015, 168, 423-432.	1.7	21

#	Article	IF	CITATIONS
91	Paraneoplastic syndrome-associated neuronal antibodies in adult ADHD. Journal of Neuroimmunology, 2015, 288, 87-91.	2.3	3
92	Mammalian CSAD and GADL1 have distinct biochemical properties and patterns of brain expression. Neurochemistry International, 2015, 90, 173-184.	3.8	26
93	Expanding the toolbox of ADHD genetics. How can we make sense of parent of origin effects in ADHD and related behavioral phenotypes?. Behavioral and Brain Functions, 2015, 11, 33.	3.3	10
94	Serum concentrations of kynurenines in adult patients with attention-deficit hyperactivity disorder (ADHD): a case–control study. Behavioral and Brain Functions, 2015, 11, 36.	3.3	40
95	Common variants in the ARC gene are not associated withÂcognitive abilities. Brain and Behavior, 2015, 5, e00376.	2.2	7
96	Genome wide association study identifies variants in NBEA associated with migraine in bipolar disorder. Journal of Affective Disorders, 2015, 172, 453-461.	4.1	15
97	Dominant Mutations in the Autoimmune Regulator AIRE Are Associated with Common Organ-Specific Autoimmune Diseases. Immunity, 2015, 42, 1185-1196.	14.3	246
98	Arc is a flexible modular protein capable of reversible self-oligomerization. Biochemical Journal, 2015, 468, 145-158.	3.7	69
99	Effects of ECT in treatment of depression: study protocol for a prospective neuroradiological study of acute and longitudinal effects on brain structure and function. BMC Psychiatry, 2015, 15, 94.	2.6	22
100	Case–Control Genome-Wide Association Study of Persistent Attention-Deficit Hyperactivity Disorder Identifies FBXO33 as a Novel Susceptibility Gene for the Disorder. Neuropsychopharmacology, 2015, 40, 915-926.	5.4	59
101	Genome-Wide Analysis of Attention Deficit Hyperactivity Disorder in Norway. PLoS ONE, 2015, 10, e0122501.	2.5	71
102	Modeling the Dynamics of Dopamine Biosynthesis and its Regulation by Tyrosine Hydroxylase. , 2014, , 30.		0
103	Phosphorylation Dependence and Stoichiometry of the Complex Formed by Tyrosine Hydroxylase and 14-3-3γ. Molecular and Cellular Proteomics, 2014, 13, 2017-2030.	3.8	19
104	Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): An open-label prospective study of time in treatment, dose, side-effects and comorbidity. European Neuropsychopharmacology, 2014, 24, 1873-1884.	0.7	48
105	Decreased serum levels of adiponectin in adult attention deficit hyperactivity disorder. Psychiatry Research, 2014, 216, 123-130.	3.3	17
106	Autoantibodies targeting neurotransmitter biosynthetic enzymes in attention-deficit/hyperactivity disorder (ADHD). European Child and Adolescent Psychiatry, 2014, 23, 115-117.	4.7	9
107	Modelling cellular signal communication mediated by phosphorylation dependent interaction with 14â€3â€3 proteins. FEBS Letters, 2014, 588, 92-98.	2.8	6
108	Functional Studies of Tyrosine Hydroxylase Missense Variants Reveal Distinct Patterns of Molecular Defects in <scp>Dopa</scp> â€Responsive Dystonia. Human Mutation, 2014, 35, 880-890.	2.5	46

#	Article	IF	CITATIONS
109	Effects of Missense Mutations in Tyrosine Hydroxylase (TH) Found in Patients with Neurological Disorders Attributed to TH Deficiency. , 2014, , 25.		0
110	Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: A review of controlled and naturalistic studies. European Neuropsychopharmacology, 2013, 23, 508-527.	0.7	125
111	Autoantibodies against aromatic amino acid hydroxylases in patients with autoimmune polyendocrine syndrome type 1 target multiple antigenic determinants and reveal regulatory regions crucial for enzymatic activity. Immunobiology, 2013, 218, 899-909.	1.9	9
112	<i>DISC1</i> in adult ADHD patients: An association study in two European samples. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2013, 162, 227-234.	1.7	16
113	Functional Properties of Rare Missense Variants of Human CDH13 Found in Adult Attention Deficit/Hyperactivity Disorder (ADHD) Patients. PLoS ONE, 2013, 8, e71445.	2.5	29
114	The genetics of attention deficit/hyperactivity disorder in adults, a review. Molecular Psychiatry, 2012, 17, 960-987.	7.9	317
115	Set-Shifting in Adults with ADHD. Journal of the International Neuropsychological Society, 2012, 18, 728-737.	1.8	50
116	The negative impact of attention-deficit/hyperactivity disorder on occupational health in adults and adolescents. International Archives of Occupational and Environmental Health, 2012, 85, 837-847.	2.3	112
117	The impact of cyclothymic temperament in adult ADHD. Journal of Affective Disorders, 2012, 142, 241-247.	4.1	40
118	Pre- and Perinatal Risk Factors in Adults with Attention-Deficit/Hyperactivity Disorder. Biological Psychiatry, 2012, 71, 474-481.	1.3	147
119	Adults with attention-deficit/hyperactivity disorder — A diffusion-tensor imaging study of the corpus callosum. Psychiatry Research - Neuroimaging, 2012, 201, 168-173.	1.8	57
120	DCLK1 Variants Are Associated across Schizophrenia and Attention Deficit/Hyperactivity Disorder. PLoS ONE, 2012, 7, e35424.	2.5	30
121	Cognitive control in adults with attention-deficit/hyperactivity disorder. Psychiatry Research, 2011, 188, 406-410.	3.3	18
122	The 14-3-3 proteins in regulation of cellular metabolism. Seminars in Cell and Developmental Biology, 2011, 22, 713-719.	5.0	131
123	Adults with Attention-Deficit/Hyperactivity Disorder ? A Brain Magnetic Resonance Spectroscopy Study. Frontiers in Psychiatry, 2011, 2, 65.	2.6	30
124	Maternal genotypes as predictors of offspring mental health: the next frontier of genomic medicine?. Future Neurology, 2011, 6, 731-743.	0.5	7
125	Bipolar disorder risk alleles in adult ADHD patients. Genes, Brain and Behavior, 2011, 10, 418-423.	2.2	17
126	No association between the serotonin transporter gene polymorphism 5-HTTLPR and cyclothymic temperament as measured by TEMPS-A Journal of Affective Disorders, 2011, 129, 308-312	4.1	11

#	Article	IF	CITATIONS
127	Glutamate cysteine ligase (GCL) and self reported depression: An association study from the HUNT. Journal of Affective Disorders, 2011, 131, 207-213.	4.1	12
128	Adult attention deficit hyperactivity disorder is associated with migraine headaches. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 595-602.	3.2	42
129	Adult attention deficit hyperactivity disorder is associated with asthma. BMC Psychiatry, 2011, 11, 128.	2.6	43
130	Attention Network Test in adults with ADHD - the impact of affective fluctuations. Behavioral and Brain Functions, 2011, 7, 27.	3.3	54
131	Exploring <i>DRD4</i> and its interaction with <i>SLC6A3</i> as possible risk factors for adult ADHD: A metaâ€analysis in four European populations. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 600-612.	1.7	22
132	DIRAS2 is Associated with Adult ADHD, Related Traits, and Co-Morbid Disorders. Neuropsychopharmacology, 2011, 36, 2318-2327.	5.4	49
133	Metaâ€analysis of brainâ€derived neurotrophic factor p.Val66Met in adult ADHD in four European populations. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 512-523.	1.7	55
134	Common variants in the TPH1 and TPH2 regions are not associated with persistent ADHD in a combined sample of 1,636 adult cases and 1,923 controls from four European populations. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 1008-1015.	1.7	18
135	Effect of pharmacological chaperones on brain tyrosine hydroxylase and tryptophan hydroxylase 2. Journal of Neurochemistry, 2010, 114, 853-863.	3.9	29
136	An international multicenter association study of the serotonin transporter gene in persistent ADHD. Genes, Brain and Behavior, 2010, 9, 449-458.	2.2	55
137	A genomeâ€wide association study of bipolar disorder and comorbid migraine. Genes, Brain and Behavior, 2010, 9, 673-680.	2.2	40
138	A common variant of the latrophilin 3 gene, LPHN3, confers susceptibility to ADHD and predicts effectiveness of stimulant medication. Molecular Psychiatry, 2010, 15, 1053-1066.	7.9	245
139	Decorin Accumulation Contributes to the Stromal Opacities Found in Congenital Stromal Corneal Dystrophy. , 2010, 51, 5578.		40
140	Multicenter Analysis of the SLC6A3/DAT1 VNTR Haplotype in Persistent ADHD Suggests Differential Involvement of the Gene in Childhood and Persistent ADHD. Neuropsychopharmacology, 2010, 35, 656-664.	5.4	180
141	Clinical assessment and diagnosis of adults with attention-deficit/hyperactivity disorder. Expert Review of Neurotherapeutics, 2010, 10, 1569-1580.	2.8	100
142	Attention-Deficit/Hyperactivity Disorder Symptoms in Offspring of Mothers With Impaired Serotonin Production. Archives of General Psychiatry, 2010, 67, 1033-1043.	12.3	47
143	Bipolar Symptoms in Adult Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychiatry, 2010, 71, 48-57.	2.2	58
144	Three-way Interaction between 14-3-3 Proteins, the N-terminal Region of Tyrosine Hydroxylase, and Negatively Charged Membranes. Journal of Biological Chemistry, 2009, 284, 32758-32769.	3.4	40

#	Article	IF	CITATIONS
145	Occupational Outcome in Adult ADHD: Impact of Symptom Profile, Comorbid Psychiatric Problems, and Treatment. Journal of Attention Disorders, 2009, 13, 175-187.	2.6	241
146	Pulmonary autoimmunity as a feature of autoimmune polyendocrine syndrome type 1 and identification of KCNRG as a bronchial autoantigen. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4396-4401.	7.1	98
147	Association between Catechol Oâ€methyltransferase (<i>COMT</i>) haplotypes and severity of hyperactivity symptoms in Adults. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009, 150B, 403-410.	1.7	55
148	Functional properties of missense variants of human tryptophan hydroxylase 2. Human Mutation, 2009, 30, 787-794.	2.5	40
149	Case-Control Study of Six Genes Asymmetrically Expressed in the Two Cerebral Hemispheres: Association of BAIAP2 with Attention-Deficit/Hyperactivity Disorder. Biological Psychiatry, 2009, 66, 926-934.	1.3	59
150	Tryptophan as an evolutionarily conserved signal to brain serotonin: Molecular evidence and psychiatric implications. World Journal of Biological Psychiatry, 2009, 10, 258-268.	2.6	59
151	Tryptophan as an evolutionarily conserved signal to brain serotonin: Molecular evidence and psychiatric implications. World Journal of Biological Psychiatry, 2009, 10, 1-11.	2.6	28
152	Oxygen dependence of tyrosine hydroxylase. Amino Acids, 2008, 34, 455-464.	2.7	8
153	Mutations in human monoamine-related neurotransmitter pathway genes. Human Mutation, 2008, 29, 891-902.	2.5	92
154	Cenetic analyses of dopamine related genes in adult ADHD patients suggest an association with the DRD5â€microsatellite repeat, but not with DRD4 or SLC6A3 VNTRs. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 1470-1475.	1.7	72
155	Endogenous tetrahydroisoquinolines associated with Parkinson's disease mimic the feedback inhibition of tyrosine hydroxylase by catecholamines. FEBS Journal, 2008, 275, 2109-2121.	4.7	12
156	A loss-of-function mutation in tryptophan hydroxylase 2 segregating with attention-deficit/hyperactivity disorder. Molecular Psychiatry, 2008, 13, 365-367.	7.9	41
157	Tetrahydrobiopterin shows chaperone activity for tyrosine hydroxylase. Journal of Neurochemistry, 2008, 106, 672-681.	3.9	48
158	Activation and stabilization of human tryptophan hydroxylase 2 by phosphorylation and 14-3-3 binding. Biochemical Journal, 2008, 410, 195-204.	3.7	60
159	Selectivity and Affinity Determinants for Ligand Binding to the Aromatic Amino Acid Hydroxylases. Current Medicinal Chemistry, 2007, 14, 455-467.	2.4	46
160	Brain-specific tryptophan hydroxylase 2 (TPH2): a functional Pro206Ser substitution and variation in the 5'-region are associated with bipolar affective disorder. Human Molecular Genetics, 2007, 17, 87-97.	2.9	109
161	Epitope mapping of human aromatic l-amino acid decarboxylase. Biochemical and Biophysical Research Communications, 2007, 353, 692-698.	2.1	1
162	A systematic intervention to improve patient information routines and satisfaction in a psychiatric emergency unit. Nordic Journal of Psychiatry, 2007, 61, 213-218.	1.3	17

#	Article	IF	CITATIONS
163	Characterization of wild-type and mutant forms of human tryptophan hydroxylase 2. Journal of Neurochemistry, 2007, 100, 1648-1657.	3.9	31
164	The regulatory phosphorylated serine in full-length nitrate reductase is necessary for optimal binding to a 14-3-3 protein. Plant Science, 2006, 170, 394-398.	3.6	3
165	An oxygraphic method for determining kinetic properties and catalytic mechanism of aromatic amino acid hydroxylases. Analytical Biochemistry, 2005, 343, 100-105.	2.4	4
166	Different properties of the central and peripheral forms of human tryptophan hydroxylase. Journal of Neurochemistry, 2005, 92, 311-320.	3.9	142
167	Stimulation of hepatic phenylalanine hydroxylase activity but not Pah-mRNA expression upon oral loading of tetrahydrobiopterin in normal mice. Molecular Genetics and Metabolism, 2005, 86, 153-155.	1.1	24
168	Tetrahydrobiopterin Binding to Aromatic Amino Acid Hydroxylases. Ligand Recognition and Specificity. Journal of Medicinal Chemistry, 2004, 47, 5962-5971.	6.4	18
169	Different stabilities and denaturation pathways for structurally related aromatic amino acid hydroxylases. FEBS Letters, 2004, 565, 155-159.	2.8	6
170	Expression and purification of human tryptophan hydroxylase from Escherichia coli and Pichia pastoris. Protein Expression and Purification, 2004, 33, 185-194.	1.3	36
171	Three-Dimensional Structure of Human Tryptophan Hydroxylase and Its Implications for the Biosynthesis of the Neurotransmitters Serotonin and Melatonin [,] . Biochemistry, 2002, 41, 12569-12574.	2.5	164
172	Regulation of tyrosine hydroxylase by stress-activated protein kinases. Journal of Neurochemistry, 2002, 83, 775-783.	3.9	94
173	Phosphorylation of Tyrosine Hydroxylase in Isolated Mice Adrenal Glands. Annals of the New York Academy of Sciences, 2002, 971, 66-68.	3.8	13
174	The Conformation of Tetrahydro-Biopterin Free and Bound to Aromatic Amino Acid Hydroxylases and NOS. , 2002, , 67-72.		0
175	Role of PHE313/TRP326 in Determining Substrate Specificity in Tryptophan and Phenylalanine Hydroxylases. , 2002, , 97-102.		0
176	A Phenylalanine Hydroxylase Amino Acid Polymorphism with Implications for Molecular Diagnostics. Molecular Genetics and Metabolism, 2001, 73, 280-284.	1.1	10
177	Conformation of the Substrate and Pterin Cofactor Bound to Human Tryptophan Hydroxylase. Important Role of Phe313 in Substrate Specificity. Biochemistry, 2001, 40, 15591-15601.	2.5	60
178	Interaction of phosphorylated tyrosine hydroxylase with 14-3-3 proteins: evidence for a phosphoserine 40-dependent association. Journal of Neurochemistry, 2001, 77, 1097-1107.	3.9	62
179	A Structural Approach into Human Tryptophan Hydroxylase and its Implications for the Regulation of Serotonin Biosynthesis. Current Medicinal Chemistry, 2001, 8, 1077-1091.	2.4	61
180	Inhibition of aromatic l -amino acid decarboxylase activity by human autoantibodies. Clinical and Experimental Immunology, 2000, 120, 420-423.	2.6	8

#	Article	IF	CITATIONS
181	Pteridin-Dependent Hydroxylases as Autoantigens in Autoimmune Polyendocrine Syndrome Type I1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2944-2950.	3.6	30
182	Identification of Tyrosine Hydroxylase as an Autoantigen in Autoimmune Polyendocrine Syndrome Type I. Biochemical and Biophysical Research Communications, 2000, 267, 456-461.	2.1	80
183	A Kinetic and Conformational Study on the Interaction of Tetrahydropteridines with Tyrosine Hydroxylaseâ€. Biochemistry, 2000, 39, 13676-13686.	2.5	25
184	Pteridin-Dependent Hydroxylases as Autoantigens in Autoimmune Polyendocrine Syndrome Type I. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2944-2950.	3.6	29
185	Urea-induced Denaturation of Human Phenylalanine Hydroxylase. Journal of Biological Chemistry, 1999, 274, 33251-33258.	3.4	28
186	Iron coordination geometry in full-length, truncated, and dehydrated forms of human tyrosine hydroxylase studied by Mössbauer and X-ray absorption spectroscopy. Journal of Biological Inorganic Chemistry, 1999, 4, 223-231.	2.6	18
187	Tyrosine hydroxylase and Parkinson's disease. Molecular Neurobiology, 1998, 16, 285-309.	4.0	211
188	Identification of tryptophan hydroxylase as an intestinal autoantigen. Lancet, The, 1998, 352, 279-283.	13.7	168
189	Human Tyrosine Hydroxylase Isoforms. Journal of Biological Chemistry, 1998, 273, 10196-10201.	3.4	38
190	15 A stress-activated kinase cascade can mediate the activation of tyrosine hydroxylase in chromaffin cells. Biochemical Society Transactions, 1997, 25, S571-S571.	3.4	3
191	The Effect of Phosphorylation at Ser-40 on the Structure and Thermal Stability of Tyrosine Hydroxylase. Advances in Pharmacology, 1997, 42, 15-18.	2.0	6
192	Crystallization and preliminary diffraction analysis of a truncated homodimer of human phenylalanine hydroxylase. FEBS Letters, 1997, 406, 171-174.	2.8	18
193	Participation of a Stress-Activated Protein Kinase Cascade in the Activation of Tyrosine Hydroxylase in Chromaffin Cells. FEBS Journal, 1997, 247, 1180-1189.	0.2	53
194	Spontaneous mutation frequencies and spectra in p53 (+/+) and p53 (â^'/â^') mice: A test of the `guardian of the genome' hypothesis in the Big Blue® transgenic mouse mutation detection system. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1997, 379, 13-20.	1.0	39
195	<scp>l</scp> â€ÐOPA Is a Substrate for Tyrosine Hydroxylase. Journal of Neurochemistry, 1997, 69, 1720-1728.	3.9	36
196	Generation of Reactive Oxygen Species by Tyrosine Hydroxylase: A Possible Contribution to the Degeneration of Dopaminergic Neurons?. Journal of Neurochemistry, 1997, 68, 328-332.	3.9	69
197	Bi-directional Dideoxy Fingerprinting (Bi-ddF): Rapid and Efficient Screening for Mutations in the Big BlueTM Transgenic Mouse Mutation Detection System. BioTechniques, 1996, 20, 988-994.	1.8	14
198	Characterization of a novel pterin intermediate formed in the catalytic cycle of tyrosine hydroxylase. Biochemical Journal, 1996, 319, 947-951.	3.7	6

#	Article	IF	CITATIONS
199	Mossbauer, Electron-Paramagnetic-Resonance and X-ray-Absorption Fine-Structure Studies of the Iron Environment in Recombinant Human Tyrosine Hydroxylase. FEBS Journal, 1996, 241, 432-439.	0.2	41
200	Structure/Function Relationships in Human Phenylalanine Hydroxylase. Effect of Terminal Deletions on the Oligomerization, Activation and Cooperativity of Substrate Binding to the Enzyme. FEBS Journal, 1996, 242, 813-821.	0.2	84
201	System issues: Spontaneous mutation in Big Blue® transgenic mice: Analysis of age, gender, and tissue type. Environmental and Molecular Mutagenesis, 1996, 28, 299-312.	2.2	57
202	Mutational specificity: Mutation frequencies butnot mutant frequencies in Big Blue® mice fit a Poisson distribution. Environmental and Molecular Mutagenesis, 1996, 28, 414-417.	2.2	31
203	Conformational Properties and Stability of Tyrosine Hydroxylase Studied by Infrared Spectroscopy. Journal of Biological Chemistry, 1996, 271, 19737-19742.	3.4	79
204	System issues: Spontaneous mutation in Big Blue® transgenic mice: Analysis of age, gender, and tissue type. Environmental and Molecular Mutagenesis, 1996, 28, 299-312.	2.2	0
205	Mutational specificity: Mutation frequencies but not mutant frequencies in Big Blue® mice fit a Poisson distribution. Environmental and Molecular Mutagenesis, 1996, 28, 414-417.	2.2	0
206	Pteridines CVII* Synthesis of 6-Azidomethyl-5,6,7,8-tetrahydropterin. Photo degradation Products and Cofactor Properties on Aromatic Amino Acid Monooxygenases. Pteridines, 1995, 6, .	0.5	1
207	XAFS of human tyrosine hydroxylase. Physica B: Condensed Matter, 1995, 208-209, 717-718.	2.7	0
208	XAS studies of human tyrosine hydroxylase. Journal of Inorganic Biochemistry, 1995, 59, 382.	3.5	1
209	Resonance Raman Studies of Catecholate and Phenolate Complexes of Recombinant Human Tyrosine Hydroxylase. Biochemistry, 1995, 34, 5504-5510.	2.5	99
210	Tryptophan Fluorescence of Human Phenylalanine Hydroxylase Produced in Escherichia coli. Biochemistry, 1995, 34, 11790-11799.	2.5	50
211	Phosphorylation and activation of human tyrosine hydroxylase in vitro by mitogen-activated protein (MAP) kinase and MAP-kinase-activated kinases 1 and 2. FEBS Journal, 1993, 217, 715-722.	0.2	164
212	Conformation and interaction of phenylalanine with the divalent cation at the active site of human recombinant tyrosine hydroxylase as determined by proton NMR. Biochemistry, 1993, 32, 6381-6390.	2.5	35
213	Expression of Wild Type and Mutant Forms of Human Phenylalanine Hydroxylase in E. Coli. Advances in Experimental Medicine and Biology, 1993, 338, 59-62.	1.6	21
214	Characterization of the Iron Environment in Recombinant Human Tyrosine Hydroxylase, Using Mössbauer and EPR-Spectroscopy. Advances in Experimental Medicine and Biology, 1993, 338, 71-76.	1.6	2
215	Interaction of Substrate and Pterin Cofactor with the Metal of Human Tyrosine Hydroxylase as Determined by 1H-NMR. Advances in Experimental Medicine and Biology, 1993, 338, 77-80.	1.6	11
216	Inactivation of purified phenylalanine hydroxylase by dithiothreitol. Biochemical and Biophysical Research Communications, 1992, 182, 92-98.	2.1	16

#	Article	IF	CITATIONS
217	7-Substituted pterins in humans with suspected pterin-4a-carbinolamine dehydratase deficiency. Mechanism of formation via non-enzymatic transformation from 6-substituted pterins. FEBS Journal, 1992, 208, 139-144.	0.2	35
218	Regulation of recombinant human tyrosine hydroxylase isozymes by catecholamine binding and phosphorylation. Structure/activity studies and mechanistic implications. FEBS Journal, 1992, 209, 249-255.	0.2	82
219	The incorporation of divalent metal ions into recombinant human tyrosine hydroxylase apoenzymes studied by intrinsic fluorescence and 1H-NMR spectroscopy. FEBS Journal, 1992, 210, 23-31.	0.2	38
220	High-molecular-mass complexes of the regulatory subunits of cyclic AMP-dependent protein kinase. Biochemical Society Transactions, 1991, 19, 1163-1165.	3.4	3
221	EPR and 1H-NMR spectroscopic studies on the paramagnetic iron at the active site of phenylalanine hydroxylase and its interaction with substrates and inhibitors. FEBS Journal, 1991, 198, 675-682.	0.2	36
222	Recombinant human tyrosine hydroxylase isozymes. Reconstitution with iron and inhibitory effect of other metal ions. FEBS Journal, 1991, 199, 371-378.	0.2	100
223	Cooperative homotropic interaction of l-noradrenaline with the catalytic site of phenylalanine 4-monooxygenase. FEBS Journal, 1990, 193, 211-219.	0.2	32
224	pH-dependent release of catecholamines from tyrosine hydroxylase and the effect of phosphorylation of Ser-40. FEBS Letters, 1990, 262, 363-365.	2.8	65
225	Identification of protein phosphatase 2A as the major tyrosine hydroxylase phosphatase in adrenal medulla and corpus striatum: evidence from the effects of okadaic acid. FEBS Letters, 1989, 251, 36-42.	2.8	102
226	Evidence from EPR spectroscopy that phosphorylation of Ser-40 in bovine adrenal tyrosine hydroxylase facilitates the reduction of high-spin Fe(III) under turnover conditions. FEBS Letters, 1989, 258, 9-12.	2.8	20
227	Native and Phosphorylated Bovine Adrenal Tyrosine 3-Monooxygenase. Interactions with Tetrahydropterins and Substrate and Stability of the Formed 4a-Hydroxy-Tetrahydrobiopterin. Pteridines, 1989, 1, 11-16.	0.5	6
228	Soluble tyrosine hydroxylase (tyrosine 3-monooxygenase) from bovine adrenal medulla: Large-scale purification and physicochemical properties. BBA - Proteins and Proteomics, 1988, 953, 142-156.	2.1	82
229	Isolation and characterization of tetrahydropterin oxidation products generated in the tyrosine 3-monooxygenase (tyrosine hydroxylase) reaction. FEBS Journal, 1987, 168, 21-26.	0.2	48
230	Stereoselective effects in the interactions of pterin cofactors with rat-liver phenylalanine 4-monooxygenase. FEBS Journal, 1986, 160, 1-8.	0.2	37
231	Isolation from the microsomal fraction of rat liver of a subfraction highly enriched in uncoated endocytic vesicles with high H+ -ATPase activity and a 50 kDa phosphoprotein. FEBS Letters, 1985, 188, 273-280.	2.8	7
232	Isolation and characterization of quinonoid dihydropterins by high-performance liquid chromatography. Journal of Chromatography A, 1983, 257, 361-372.	3.7	19
233	Fluorometric detection of tryptophan, 5-hydroxytryptophan, and 5-hydroxytryptamine (serotonin) in high-performance liquid chromatography. Analytical Biochemistry, 1980, 107, 71-74.	2.4	33
234	Rapid and sensitive assay of tyrosine 3-monooxygenase activity by high-performance liquid chromatography using the native fluorescence of DOPA. Journal of Chromatography A, 1980, 198, 511-515.	3.7	41

#	Article	IF	CITATIONS
235	Genome Guided Personalized Drug Therapy in Attention Deficit Hyperactivity Disorder. Frontiers in Psychiatry, 0, 13, .	2.6	3